Wan Ting Tee

UON MPharm 🎓 | independent Prescriber | Cardiovascular Pharmacist @gsttNHS 🫀 | interest in endocrinology, cardiology, haematology, and respiratory.

[Dr Rani Khatib FESC @DrRaniKhatib]

Deprescribing...
We often want to prescribe as clinicians... but what about deprescribing? It needs to be part of our clinical practice.
#EASCongress2025 @EASCongress

[Wan Ting Tee @wantingtee]

@betway @ChelseaFC 3-0 chelsea! 💙

[Words @itswords_]

reminder

[Wan Ting Tee @wantingtee]

@betway @ChelseaFC 2-1 chelsea !!! 😙

[Wasim Baqir @wasimbaqir]

An essential resource for ICBs and healthcare professionals supporting people who take multiple medicines.

Launch of new “game changing” guide to tackle overprescribing and support Government’s shifts to prevention and community

https://t.co/m7zOJ5Teo1

[GoggleDocs @GoggleDocs]

Finerenone on kidney outcomes in HFmrEF/HFpEF❗️

🔹 FINEARTS-HF trial: Reduced new-onset macroalbuminuria by 38% (HR: 0.62) & microalbuminuria by 24% (HR: 0.76).

🔸Acute eGFR decline noted, but no significant impact on long-term kidney outcomes.

🔗 https://t.co/plpWreiulG

[Dr. AK 🇮🇳 @docakx]

🌟DOAC : When Not to use?

[GoggleDocs @GoggleDocs]

SGLT-2 inhibitors ⤵️ cirrhosis risk in #T2D❗️

🔹 🇬🇧 cohort study: SGLT-2 inhibitors ⤵️cirrhosis incidence by 36% (HR 0.64) & decompensated cirrhosis by 26% (HR 0.74) vs. DPP-4i's.

🔹 No similar benefit seen with #GLP1

��Highlights potential liver benefits of SGLT-2 inhibitors

🔗https://t.co/2zwqV5VYwn

@drshafikuchay @kamleshkhunti

[Jasmine Sethi @JasmineNephro]

❤️‍🩹Heart failure with preserved EF

@NEJM

https://t.co/44IInQKsin

[Ahmed Mohsen @drahmedmohsen85]

Very precious Cardiology Pearls (2)
👌💪🔥✌️😁

From my book "Tips and Tricks in Cardiology "

Contact me if you are interested in getting a copy

[Dr Paddy Barrett @Paddy_Barrett]

As a Cardiologist, here are some of the biggest mistakes I see patients make.

🧵👇

/1

[Lama Alghamdi @Ph_LamaAlghamdi]

HFrEF Treatment 🫀

[Brendon Neuen @brendonneuen]

Clear reductions in all outcomes with GLP-1RA:

Kidney failure ✅
Major CV events ✅
Heart failure ✅
CV death ✅
All-cause death ✅

Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes

Now in @TheLancetEndo https://t.co/o60CmZeZgm

[Apoorva Gangavelli, MD, MSc @AGangavelli]

🏥New to the CCU? Not sure how to manage temporary mechanical circulatory support?

⭐️Check out our new @CardioNerds infographic on using TMCS in cardiogenic shock! Explore their mechanisms, management, and waveforms you need to know!

[Dr. AK 🇮🇳 @docakx]

🌟 ORAL HYPOGLYCEMIC DRUGS - Dosing in CKD

🔸️As per latest recommendations Dapagliflozin can be initiated at eGFR > 20 and continued till RRT.

Also pioglitazone doesn't require dose adjustment for any stage of CKD.

[JACC Journals @JACCJournals]

In this #JACCIMG state-of-the-art review, learn the utility of #whyCMR for assessment of adverse LV remodeling post-MI, including pathophysiology, prognosis, clinical trial data, & treatment approaches. https://t.co/p5MwXzdBzU

#cvMI #HeartFailure @chrisgraeni

[ASN Publications @asnpublications]

The effect of sodium-glucose co-transporter-2 inhibitors (SGLT2i) on cardiovascular disease and CKD may be limited if discontinued in persons with CKD. This study found that a substantial proportion of patients experience SGLT2i discontinuation within a year of initiation. https://t.co/0ciXlk7Q2Z
@estrella_khrc
@j_ikeme
@cdchu
@shlipak_khrc
@NephroNinja
@KHRC_research

[Abdulla A. Damluji, MD, PhD @DrDamluji]

Left Atrial Appendage Closure after Ablation for Atrial Fibrillation: @NEJM

🥸The OPTION trial: @AHAScience

😱 Summary

👇👇👇👇

[AHA Science @AHAScience]

BPROAD Presented at #AHA24

Intensive SBP lowering in people with Type 2 diabetes and elevated SBP could be beneficial for reducing cardiovascular events, but increased risks of hyperkalemia and symptomatic hypotension suggest the need for careful monitoring.

[Scott Isaacs @scottisaacsmd]

New data from the SUMMIT trial: #tirzepatide reduced the risk of worsening heart failure events by 38% in adults with heart failure with preserved ejection fraction #HFpEF and obesity.
https://t.co/GXqIpC4iu6